Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | HPGD | P15428 | 7/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.63 |
| ▸ | GAA | P10253 | 6/20 | 0.63 |
| ▸ | GLA | P06280 | 5/20 | 0.63 |
| ▸ | CASP1 | P29466 | 5/20 | 0.63 |
| ▸ | CASP7 | P55210 | 5/20 | 0.63 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17717500 | 1.00 | ATM (1.00) | ATMARKDM4EALDH1A1HPGD | |
| SCHEMBL11028692 | 0.91 | ATM (0.84) | ATMARKDM4EALDH1A1HPGD | |
| SCHEMBL3196150 | 0.81 | ATM (0.68) | ATMARKDM4EALDH1A1HPGD | |
| SCHEMBL3196293 | 0.80 | ATM (0.67) | ATMARKDM4EALDH1A1HPGD | |
| SCHEMBL29474210 | 0.80 | AR (1.00) | ATMARCASP1CASP7MCL1 | |
| SCHEMBL5234524 | 0.79 | ATM (0.64) | ATMARKDM4EALDH1A1HPGD | |
| SCHEMBL5229367 | 0.79 | ATM (0.64) | ATMARKDM4EALDH1A1HPGD | |
| SCHEMBL5234530 | 0.79 | ATM (0.64) | ATMARKDM4EALDH1A1HPGD | |
| SCHEMBL14561715 | 0.79 | ATM (0.64) | ATMARKDM4EALDH1A1HPGD | |
| SCHEMBL17717371 | 0.78 | ATM (0.64) | ATMARKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201624-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | IMMUNOLIGHT, LLC (US) | 2023-06-29 | — | — | US | claimed |
| US-20230292413-A1 | UP AND DOWN CONVERSION SYSTEMS FOR PRODUCTION OF EMITTED LIGHT FROM VARIOUS ENERGY SOURCES INCLUDING RADIO FREQUENCY, MICROWAVE ENERGY AND MAGNETIC INDUCTION SOURCES FOR UPCONVERSION | IMMUNOLIGHT, LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11589432-B2 | Up and down conversion systems for production of emitted light from various energy sources including radio frequency, microwave energy and magnetic induction sources for upconversion | IMMUNOLIGHT, LLC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11324965-B2 | Non-invasive energy upconversion methods and systems | IMMUNOLOIGHT, LLC. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201624-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | MAVS, NLN, FURIN | ATM 3942/4885AR 4694/4885KDM4E 4490/4885 |
| US-11324965-B2 | Non-invasive energy upconversion methods and systems | FURIN, NFATC1, HAVCR2 | ATM 4271/4885AR 4531/4885KDM4E 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.